Immunology Market by Drug Class (Fusion Proteins, Immunosuppressants, Monoclonal Antibody (mAb), Polyclonal Antibody (pAb)), Disease Indication, Distribution Channel, and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030

Immunology Market by Drug Class (Fusion Proteins, Immunosuppressants, Monoclonal Antibody (mAb), Polyclonal Antibody (pAb)), Disease Indication, Distribution Channel, and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030

Immunology Market Size

The global immunology market size was valued at $109.02 billion in 2024 and is projected to reach $203.92 billion by 2030, growing at a CAGR of 11.0% during the forecast period.

Immunology Market Overview

Immunology is the branch of biomedical science focused on the study of the immune system, which is crucial for defending the body against infections and diseases. It encompasses understanding how the immune system recognizes and responds to harmful pathogens, allergens, and other foreign substances. The immune system consists of two main components: innate immunity, which provides immediate but non-specific defense, and adaptive immunity, which develops a targeted response to specific threats and retains memory of past infections for quicker responses in the future.

Understanding immunological mechanisms allows companies to develop targeted therapies, such as monoclonal antibodies and immunotherapies, which can treat various conditions, including cancer, autoimmune diseases, and allergies. This is particularly relevant as the global market for immunological drugs is expected to grow significantly.

Immunology Market Dynamics

The immunology market is expected to witness significant growth in the future due to increasing prevalence of autoimmune diseases and allergies, advancements in biotechnology and molecular medicine, growing adoption of immunotherapy in cancer treatment, and the rising investments in research and development. However, the high cost of immunotherapy treatments and stringent regulatory requirements are restraining the growth of the market.

Furthermore, development of personalized immunotherapies, increasing collaboration between academic institutions and pharmaceutical companies, technological advancements in diagnostic biomarkers, and the growing focus on preventive immunology are the key trends propelling the immunology market.

Increasing Prevalence of Autoimmune Diseases and Allergies is driving the Immunology Market

The increasing prevalence of autoimmune diseases and allergies is significantly impacting the immunology market, leading to heightened demand for innovative therapies and treatments. Various environmental factors, such as exposure to toxic chemicals, stress, dietary components, gut dysbiosis, and infections, contribute to a substantial patient population suffering from autoimmune diseases. Autoimmune diseases now rank as the third most common cause of chronic illness in the U.S., affecting approximately 50 million people with at least one form of the condition.

• For instance, a population-based study conducted by the University of Oxford in May 2023 found that one in ten individuals, out of 22.0 million surveyed, is affected by autoimmune disorders. This rising demand for treatments among patients is prompting market players to develop and launch new drugs in the global immunology market.
• Moreover, the incidence of autoimmune diseases is on the rise, with estimates indicating a 19.1% increase in the overall worldwide incidence and a 12.5% increase in prevalence annually. This trend is largely attributed to environmental factors, including pollution, dietary changes, and lifestyle modifications

The growing number of regulatory approvals for new drugs targeting autoimmune disorders is further fueling market growth.

• For example, in February 2023, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) had approved Kevzara for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease.

Market growth is expected to be bolstered over the forecast period by increasing awareness of autoimmune disorders in both developed and developing countries, as well as the potential for promising pipeline candidates.

By Disease Indication, the Rheumatoid Arthritis Segment Constitutes Immense Share with Immunology Market

The rheumatoid arthritis segment holds a significant share within the immunology market owing to the chronic nature of the disease, which affects millions globally and often leads to significant disability if untreated. The increasing number of patients seeking treatment, coupled with the rising prevalence of rheumatoid arthritis, will drive higher demand for drugs used in its treatment.

• According to the data published by the Australian Bureau of Statistics in 2023 estimated that 3.7 million people in Australia were affected by arthritis, with 13.9% of them suffering from rheumatoid arthritis.

Advances in understanding the immunopathology of RA have driven the development of targeted biologic therapies that modify the immune response, offering more effective and personalized treatment options.

• For instance, the approval of new drugs, such as Rinvoq (upadacitinib), which received FDA approval in mid-2019, has significantly contributed to market growth. Rinvoq is experiencing a 43% year-on-year growth in sales within the RA market, making it a major growth driver alongside adalimumab, which remains the market leader.

Companies like AbbVie and Johnson & Johnson are at the forefront of this growth, supported by favorable regulatory conditions that encourage the development and introduction of new therapies. As the market continues to evolve, the focus on personalized medicine and targeted therapies will likely enhance treatment effectiveness and patient outcomes.

• For example, AbbVie continues to innovate with its flagship product, Humira (adalimumab), and has been actively involved in the development of biosimilars to maintain its market presence.
• Similarly, Johnson & Johnson is also heavily invested in research and development for new immunology therapies, focusing on enhancing treatment outcomes for RA patients

Additionally, increasing awareness, early diagnosis, and the aging population contribute to the rising demand, as RA prevalence typically increases with age.

By Geography, Asia Pacific is Projected to Grow at the Highest CAGR in the Immunology Market

Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period due to the increasing healthcare expenditures, a rising prevalence of autoimmune diseases, and robust research and development initiatives. Notably, between 2010 and 2020, there was a 39% increase in immunology-related clinical trials in the region, with China leading the way, accounting for 43.5% of all trials conducted in Asia Pacific. This surge indicates a growing focus on developing innovative therapies tailored to address the unique healthcare challenges faced by the population. Companies such as Pfizer and Amgen are actively contributing to this growth through strategic initiatives.

• For instance, in February 2022, Pfizer acquired Arena Pharmaceuticals, enhancing its portfolio with therapies aimed at immune-inflammatory disorders. Additionally, Amgen received FDA approval for its immunology drug Otezla in December 2021, targeting conditions like plaque psoriasis, which is prevalent in the region.

Government initiatives also play a crucial role; countries like India and Japan are increasing their healthcare budgets and investing in research to tackle autoimmune diseases more effectively. These factors collectively position the Asia Pacific region as a burgeoning hub for immunology, with an expanding market that is set to meet the growing demand for effective therapies.

Key Target Audience:

• Pharmaceutical and Biotechnology Firms
• Healthcare Providers
• Regulatory Agencies
• Research and Academic Institutions
• Patients and Patient Advocacy Groups
• Investors and Venture Capitalists
• Contract Research Organizations (CROs)

List of the Key Players Profiled in the Report Includes:

• Abbvie Inc.
• ALLERGAN
• Amgen Inc.
• Astellas
• AstraZeneca
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Janssen Global Service,LLC (Johnson and Johnson)
• Merck Sharp and Dohme Corp.
• Novartis AG
• Pfizer Inc.
• UCB SA

Recent Developments:

• In May 2024, AstraZeneca highlighted the potential for significant cost savings for health systems in four European countries through early screening and treatment of chronic kidney disease (CKD). By preventing numerous heart attacks, heart failure hospitalizations, and strokes, early intervention could lead to substantial healthcare savings. Studies presented at the ERA Congress underscored the benefits of targeted screening and guideline-directed treatment, demonstrating both clinical advantages and potential cost reductions.
• In February 2024, AbbVie and OSE Immunotherapeutics announced a partnership to develop OSE-230, a monoclonal antibody for chronic inflammation treatment.
• In January 2024, Janssen Global Services, LLC (Johnson & Johnson) announced the launch of Tremfya for ulcerative colitis, expanding its immunology offerings. TREMFYA is the first fully human, dual-acting monoclonal antibody approved for use, specifically designed to block IL-23 while also binding to CD64, a receptor found on cells that produce IL-23. IL-23 is a cytokine secreted by activated monocytes, macrophages, and dendritic cells, and is recognized as a key driver of immune-mediated diseases, including Crohn's disease.

Market Segmentation:

The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments:

Market by, Drug Class:

• Fusion Proteins
• Immunosuppressants
• Monoclonal Antibody (mAb)
• Polyclonal Antibody (pAb)
• Other Drug Classes

Market by, Disease Indication:

• Ankylosing Spondylitis
• Inflammatory Bowel Disease
• Plaque Psoriasis
• Prophylaxis of Organ Rejection
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Other Disease Indications

Market by, Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Other Distribution Channels

Market by, Geography:

The immunology market report also analyzes the major geographic regions and countries of the market. The regions and countries covered in the study include:

• North America (The United States, Canada, Mexico), Market Estimates, Forecast & Opportunity Analysis
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Market Estimates, Forecast & Opportunity Analysis
• Asia Pacific (China, Japan, India, South Korea, Australia, New Zealand, Rest of Asia Pacific), Market Estimates, Forecast & Opportunity Analysis
• South America (Brazil, Argentina, Chile, Rest of South America), Market Estimates, Forecast & Opportunity Analysis
• Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, Rest of Middle East & Africa), Market Estimates, Forecast & Opportunity Analysis

Scope of the Report:

The report “Global Immunology Market: Industry Analysis, Opportunities and Forecast up to 2030” by Diligence Insights provides a detailed analysis of the present market and future outlook with market estimates and forecasts for all specified segments, encompassing both global and regional perspectives as outlined within the research framework. The study includes historical market data for the years 2022, 2023 and offers revenue estimations for 2024, and project forecasts spanning from 2025 to 2030. It places significant emphasis on the examination of market trends, key industry participants, supply chain developments, technological advancements, pivotal milestones, and prospective strategies. Comprehensive market assessments are carried out across major geographic regions, including North America, Europe, Asia Pacific, South America, and Middle East & Africa. As such, this report constitutes a valuable resource for current industry stakeholders, newcomers to the field, and potential investors.

The study offers an in-depth market analysis, drawing insights from industry experts across the value chain. A special focus has been made on 25 countries, including the United States, Canada, Mexico, the United Kingdom, Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, and South Africa, among others. The market data has been meticulously collected through extensive primary interviews and comprehensive secondary research. Market size determination is rooted in the revenue generated from sales across all the specified segments and sub-segments as defined within the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

The report offers insights into the following aspects:

• Analysis of major market trends, factors driving, restraining, threatening, and providing opportunities for the market.
• Analysis of the market structure by identifying various segments and sub-segments of the market.
• Understand the revenue forecast of the market for North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
• Analysis of opportunities by identification of high-growth segments/revenue pockets in the market.
• Understand major player profiles in the market and analyze their business strategies.
• Understand competitive developments such as joint ventures, alliances, mergers and acquisitions, and new product launches in the market.